Payment overview · 2025
General Payments
$270.60
12 reported records · 7 companies
Healthcare provider profile · identity verified
David Franklin Sutter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CORPUS CHRISTI, TX · NPI 1659351500
Verified facts
What the public records show
CMS Open Payments records show David Franklin Sutter, M.D. received $270.60 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.22 | 26.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $55.96 | 20.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.87 | 14.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.93 | 12.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.56 | 10.6% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $24.44 | 9.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.62 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $270.60 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.22 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $55.96 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 116 |
| Losartan Potassium | Losartan Potassium | 419 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 114 |
| Metformin Hcl | Metformin Hcl | 233 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 59 |
| Simvastatin | Simvastatin | 206 | 57 |
| Omeprazole | Omeprazole | 190 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 59 |
| Lisinopril | Lisinopril | 137 | 45 |
| Alprazolam | Alprazolam | 131 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 41 |
| Tramadol Hcl | Tramadol Hcl | 123 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 31 |
| Meloxicam | Meloxicam | 106 | 30 |
| Methylprednisolone | Methylprednisolone | 103 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 30 |
| Ozempic | Semaglutide | 94 | 22 |
| Celecoxib | Celecoxib | 81 | 22 |
| Allopurinol | Allopurinol | 77 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 19 |
| Farxiga | Dapagliflozin Propanediol | 74 | 21 |
| Januvia | Sitagliptin Phosphate | 73 | 15 |
| Gabapentin | Gabapentin | 72 | 27 |
| Donepezil Hcl | Donepezil Hcl | 68 | 21 |
| Furosemide | Furosemide | 67 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 21 |
| Telmisartan | Telmisartan | 61 | 18 |
| Eliquis | Apixaban | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 18 |
| Azithromycin | Azithromycin | 58 | 53 |
| Trazodone Hcl | Trazodone Hcl | 56 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 25 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 51 | 11 |
| Nifedipine Er | Nifedipine | 50 | 13 |
| Carvedilol | Carvedilol | 49 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Alendronate Sodium | Alendronate Sodium | 41 | 16 |
| Clonazepam | Clonazepam | 36 | 12 |
| Montelukast Sodium | Montelukast Sodium | 36 | 13 |
| Cefdinir | Cefdinir | 35 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 13 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 11 |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 17 |
| Glipizide | Glipizide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Prolia | Denosumab | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $270.60 · 12 records | Novo Nordisk Inc | AREXVY, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, NURTEC ODT, NUVISION ICE CATHETER, SHINGRIX, SYMPLICITY G3, TZIELD, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error